Work

A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of the H3 Receptor Antagonist, GSK239512 as a Monotherapy in Subjects with Mild-to-Moderate Alzheimer’s Disease

Year: 2014

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Current Alzheimer Research

DOI: 10.2174/1567205010666131212110148

Authors: Richard Grove, Conn Harrington, Andreas Mahler, Isabel Beresford, Paul Maruff, Martin Lowy, Andrew Nicholls, Rebecca Boardley, Alienor Berges, Pradeep Nathan, Joseph Horrigan

Institutions: GlaxoSmithKline (United States), University of Cambridge

Language: English

Topic: Alzheimer's disease research and treatments

Subfield: Cellular and Molecular Neuroscience

Field: Neuroscience

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: GlaxoSmithKline

OpenAlex ID: W2152245709

FWCI: 5.582

Cites:

Cited by: 113

Related to: 10